LAVA Therapeutics (LVTX) Competitors $1.40 -0.08 (-5.41%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.38 -0.02 (-1.43%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. IMRX, ENTA, SPRO, LXEO, THTX, GLSI, RAPT, IKT, MOLN, and LYELShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Immuneering (IMRX), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Greenwich LifeSciences (GLSI), Rapt Therapeutics (RAPT), Inhibikase Therapeutics (IKT), Molecular Partners (MOLN), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Immuneering Enanta Pharmaceuticals Spero Therapeutics Lexeo Therapeutics Theratechnologies Greenwich LifeSciences Rapt Therapeutics Inhibikase Therapeutics Molecular Partners Lyell Immunopharma Immuneering (NASDAQ:IMRX) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Does the media refer more to IMRX or LVTX? In the previous week, Immuneering had 1 more articles in the media than LAVA Therapeutics. MarketBeat recorded 2 mentions for Immuneering and 1 mentions for LAVA Therapeutics. LAVA Therapeutics' average media sentiment score of 1.89 beat Immuneering's score of 0.95 indicating that LAVA Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Immuneering Positive LAVA Therapeutics Very Positive Do analysts rate IMRX or LVTX? Immuneering currently has a consensus target price of $13.25, indicating a potential upside of 216.99%. LAVA Therapeutics has a consensus target price of $3.17, indicating a potential upside of 126.19%. Given Immuneering's stronger consensus rating and higher probable upside, equities analysts clearly believe Immuneering is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, IMRX or LVTX? LAVA Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K470.12-$61.04M-$1.96-2.13LAVA Therapeutics$11.98M3.07-$25.11M-$1.04-1.35 Is IMRX or LVTX more profitable? LAVA Therapeutics' return on equity of -86.38% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -119.22% -99.22% LAVA Therapeutics N/A -86.38%-34.12% Which has more risk and volatility, IMRX or LVTX? Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in IMRX or LVTX? 67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 9.5% of LAVA Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryLAVA Therapeutics beats Immuneering on 8 of the 15 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.93M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.3520.2228.5419.58Price / Sales3.07298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book1.327.568.145.54Net Income-$25.11M-$55.11M$3.24B$257.73M7 Day Performance2.94%3.81%0.17%-0.08%1 Month Performance8.53%11.60%5.95%8.09%1 Year Performance-33.65%-2.11%26.22%13.02% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics2.197 of 5 stars$1.40-5.4%$3.17+126.2%-22.2%$38.93M$11.98M-1.3560IMRXImmuneering3.3779 of 5 stars$4.17-5.7%$13.25+217.7%+242.6%$150.06MN/A-2.1360ENTAEnanta Pharmaceuticals3.9191 of 5 stars$6.96+6.1%$18.00+158.6%-60.2%$148.81M$67.64M-1.53160News CoverageSPROSpero Therapeutics3.9053 of 5 stars$2.64-6.0%$5.00+89.4%+72.3%$147.60M$47.98M-2.06150Positive NewsLXEOLexeo Therapeutics2.0204 of 5 stars$4.44-0.7%$16.60+273.9%-68.3%$147.41M$650K-1.3558THTXTheratechnologiesN/A$3.15flatN/A+103.9%$144.84M$85.87M-16.58140Earnings ReportGLSIGreenwich LifeSciences2.1436 of 5 stars$10.81-0.3%$39.00+260.8%-35.6%$144.53MN/A-8.583High Trading VolumeRAPTRapt Therapeutics4.3594 of 5 stars$8.72+3.1%$19.80+127.1%-62.9%$144.23M$1.53M-0.4580News CoverageAnalyst RevisionGap UpIKTInhibikase Therapeutics1.2001 of 5 stars$1.94+4.9%$6.50+235.1%+20.8%$144.22MN/A-0.736MOLNMolecular Partners3.0793 of 5 stars$3.55-1.1%$12.00+238.0%-43.5%$143.33M$2.23M-1.85180Positive NewsGap DownLYELLyell Immunopharma3.2501 of 5 stars$9.67-0.8%$15.00+55.1%-73.5%$143.19M$65K-0.39270News Coverage Related Companies and Tools Related Companies Immuneering Alternatives Enanta Pharmaceuticals Alternatives Spero Therapeutics Alternatives Lexeo Therapeutics Alternatives Theratechnologies Alternatives Greenwich LifeSciences Alternatives Rapt Therapeutics Alternatives Inhibikase Therapeutics Alternatives Molecular Partners Alternatives Lyell Immunopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LVTX Stock Alerts